Skip to Content

CNBX Pharmaceuticals Inc CNBX

Morningstar Rating
$0.01 0.00 (0.14%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CNBX is trading at a 270% premium.
Price
$0.01
Fair Value
$9.83
Uncertainty
Extreme
1-Star Price
$5.87
5-Star Price
$4.67
Economic Moat
Mbnr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CNBX is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.010.05
Bid/Ask
$0.00 / $0.02
Market Cap
$217,468.35
Volume/Avg
277,600 / 233,166

Key Statistics

Price/Earnings (Normalized)
0.02
Price/Sales
0.86
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
2

Valuation

Metric
CNBX
Price/Earnings (Normalized)
0.02
Price/Book Value
Price/Sales
0.86
Price/Cash Flow
Price/Earnings
CNBX

Financial Strength

Metric
CNBX
Quick Ratio
0.03
Current Ratio
0.03
Interest Coverage
−26.00
Quick Ratio
CNBX

Profitability

Metric
CNBX
Return on Assets (Normalized)
−180.92%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
CNBX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
ZkvrxdfpxLmmnn$565.6 Bil
Vertex Pharmaceuticals Inc
VRTX
WgvpspbZgwbvv$127.8 Bil
Regeneron Pharmaceuticals Inc
REGN
VmsfmkcGhxss$118.7 Bil
Moderna Inc
MRNA
SlqkrrhhBgbr$46.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
TxdhdghmPfsbdzl$29.7 Bil
argenx SE ADR
ARGX
MsswwczydCrlkj$29.3 Bil
BioNTech SE ADR
BNTX
VdgdcktbGlqs$20.7 Bil
Biomarin Pharmaceutical Inc
BMRN
HvlzcnmlSlbrtw$16.1 Bil
United Therapeutics Corp
UTHR
QfchdrmTxm$15.0 Bil
Incyte Corp
INCY
XcpyjsyvtPqgyrzd$13.5 Bil

Sponsor Center